185 related articles for article (PubMed ID: 36167829)
1. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T; Evans CM; Zakheim D; Chu KL; Refermat AY; Asgari Z; Yang X; Da Silva Ferreira M; Mehta S; Russo MV; Knezevic A; Zhang XP; Chen Z; Fennell M; Garippa R; Seshan V; de Stanchina E; Barbash O; Batlevi CL; Leslie CS; Melnick AM; Younes A; Kharas MG
Nat Commun; 2022 Sep; 13(1):5676. PubMed ID: 36167829
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
[TBL] [Abstract][Full Text] [Related]
3. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.
Li Y; Chitnis N; Nakagawa H; Kita Y; Natsugoe S; Yang Y; Li Z; Wasik M; Klein-Szanto AJ; Rustgi AK; Diehl JA
Cancer Discov; 2015 Mar; 5(3):288-303. PubMed ID: 25582697
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.
Chung J; Karkhanis V; Baiocchi RA; Sif S
J Biol Chem; 2019 May; 294(19):7692-7710. PubMed ID: 30885941
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F; Hwang I; Sloan S; Hinterschied C; Helmig-Mason J; Long M; Chan WK; Prouty A; Chung JH; Zhang Y; Singh S; Youssef Y; Bhagwat N; Chen Z; Chen-Kiang S; Di Liberto M; Elemento O; Sehgal L; Alinari L; Vaddi K; Scherle P; Lapalombella R; Paik J; Baiocchi RA
Blood Adv; 2023 Oct; 7(20):6211-6224. PubMed ID: 37327122
[TBL] [Abstract][Full Text] [Related]
6. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
Lu X; Fernando TM; Lossos C; Yusufova N; Liu F; Fontán L; Durant M; Geng H; Melnick J; Luo Y; Vega F; Moy V; Inghirami G; Nimer S; Melnick AM; Lossos IS
Blood; 2018 Nov; 132(19):2026-2039. PubMed ID: 30082494
[TBL] [Abstract][Full Text] [Related]
7. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
8. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
[TBL] [Abstract][Full Text] [Related]
10. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract][Full Text] [Related]
11. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
12. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
13. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
14. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Chung J; Karkhanis V; Tae S; Yan F; Smith P; Ayers LW; Agostinelli C; Pileri S; Denis GV; Baiocchi RA; Sif S
J Biol Chem; 2013 Dec; 288(49):35534-47. PubMed ID: 24189068
[TBL] [Abstract][Full Text] [Related]
16. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
17. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract][Full Text] [Related]
18. The protein arginine methyltransferase PRMT5 regulates Aβ-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
Quan X; Yue W; Luo Y; Cao J; Wang H; Wang Y; Lu Z
J Neurochem; 2015 Sep; 134(5):969-77. PubMed ID: 26086249
[TBL] [Abstract][Full Text] [Related]
19. Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2
Ichikawa T; Shanab O; Nakahata S; Shimosaki S; Manachai N; Ono M; Iha H; Shimoda K; Morishita K
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118615. PubMed ID: 31765670
[TBL] [Abstract][Full Text] [Related]
20. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Park JH; Szemes M; Vieira GC; Melegh Z; Malik S; Heesom KJ; Von Wallwitz-Freitas L; Greenhough A; Brown KW; Zheng YG; Catchpoole D; Deery MJ; Malik K
Mol Oncol; 2015 Mar; 9(3):617-27. PubMed ID: 25475372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
